Pepcid Rx-to-OTC switch
FDA's Nonprescription Drugs & Gastrointestinal Drugs Advisory Committees will consider J&J/Merck's application for over-the- counter status of the H[2]-antagonist Pepcid (famotidine) on July 29. J&J/Merck is seeking approval for the drug as an OTC for treatment and prevention of episodic heartburn. SmithKline Beecham is seeking OTC status for a similar indication for Tagamet (cimetidine); the advisory committees rejected an approval recommendation last September. However, SmithKline expects the OTC Tagamet NDA to be revisited on July 27. FDA has not yet officially announced a meeting on Tagamet
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.